1715 ET - Tilray Brands Chief Executive Irwin Simon spoke in favor of President Trump's directive to reschedule marijuana. In December, the president signed an executive order directing the Attorney General to expedite the process of making marijuana a Schedule III drug, which is defined as having a moderate or low risk of dependence, from a Schedule I. Simon said a rescheduling would pave the way for more research and better patient access to medical cannabis in the U.S. Tilray can leverage its experience researching and developing medical marijuana as the regulatory landscape progresses, Simon said. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

January 08, 2026 17:15 ET (22:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.